AIXC · AIxCrypto Holdings, Inc.

Aixcrypto Holdings, Inc. Is A Clinical-Stage Biopharmaceutical Company Committed To Discovering And Developing Innovative Treatments For Both Adult And Pediatric Oncology. Its Leading Investigational Therapeutic, Qn-302, Is A Small Molecule G-Quadruplexes (G4)-Selective Transcription Inhibitor Currently Progressing Through Phase I Clinical Trials For Pancreatic Cancer And A Range Of Other Solid Tumors. The Firm Is Also Advancing Pan-Ras, A Preclinical-Stage Program Targeting Advanced Solid Tumors. Founded In 1996 And Headquartered In Carlsbad, California, The Company Rebranded From Qualigen Therapeutics, Inc. To Aixcrypto Holdings, Inc. In November 2025.